Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.
Sign Up to like & getrecommendations! Published in 2021 at "Thoracic cancer"
DOI: 10.1111/1759-7714.14236
Abstract: BACKGROUND Chemoimmunotherapy has become a standard treatment option for patients with untreated advanced non-small-cell lung cancer (NSCLC). However, numerous patients with advanced NSCLC develop disease progression. Therefore, the selection of second-line treatment after chemoimmunotherapy is… read more here.
Keywords: docetaxel plus; cancer; chemoimmunotherapy; plus ramucirumab ... See more keywords
Osimertinib plus Ramucirumab: The Best of Both Worlds?
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-4026
Abstract: Both osimertinib and the combination of erlotinib plus ramucirumab are approved for initial therapy of advanced EGFR mutation–positive non–small cell lung cancer. Osimertinib is also approved in previously treated T790M mutation–positive patients. The accompanying article… read more here.
Keywords: plus ramucirumab; osimertinib plus; ramucirumab best; best worlds ... See more keywords
Impact of Second-line Chemotherapy on Prognosis: Response of Advanced Gastric Cancer to Taxanes Plus Ramucirumab
Sign Up to like & getrecommendations! Published in 2022 at "AntiCancer Research"
DOI: 10.21873/anticanres.15634
Abstract: Background/Aim: The impact of clinical response to taxanes plus ramucirumab (RAM) on overall survival (OS) has not been clarified for advanced gastric cancer (AGC), although this type of therapy is already in use as second-line… read more here.
Keywords: taxanes plus; plus ramucirumab; advanced gastric; gastric cancer ... See more keywords